ASCLETIS-B(01672.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 319.67 million, loss widened by 263.46% YoY
NewTimeSpace (newtimespace.com) News, August 31, 2026, ASCLETIS-B(01672.HK) released its Interim Report for the period ended December 31, 2026; Net Profit stood at loss of CNY 319.67 million, loss widened by 263.46% YoY; Profit Attributable to Shareholders stood at loss of CNY 319.67 million, loss widened by 263.46% YoY; Basic Earnings Per Share (EPS) stood at loss of CNY 0.31.
In terms of profitability, ASCLETIS-B net profit changed from loss of CNY 87.95 million in the same period last year to loss of CNY 319.67 million in the current period, decreased by CNY 231.72 million.
In terms of earnings quality, ASCLETIS-B Operating Profit changed from loss of CNY 87.86 million in the same period last year to loss of CNY 319.5 million in the current period, decreased by CNY 231.64 million.
In terms of R&D investment focus, ASCLETIS-B R&D Expenses changed from CNY 146.81 million in the same period last year to CNY 341.66 million in the current period, increased by CNY 194.85 million.
By the close of trading on August 31, 2026, ASCLETIS-B(01672) saw a loss of 0.79% in its share price, closing at HKD 10.02. The full-day turnover stood at HKD 20.5 million, showing significant volume increase, with the latest market capitalization at HKD 10.54 billion.
NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- ASCLETIS-B (01672.HK): First subject dosed in global Phase III program of oral GLP-1 agonist ASC30 for long-term weight management, targeting ~4,600 subjects
- Ascletis-B (01672.HK): Oral Small-molecule GLP-1 ASC30 Initiates Global Phase III Clinical Trials; First-in-class Triple-target FDC Achieves 15.2% Weight Loss in Preclinical Studies
- ASCLETIS-B (01672.HK): ASC36_35 FDC Exhibits Superior Weight-Loss Efficacy versus Eloralintide Combined with Tirzepatide; Preclinical Data to Be Presented at EASD 2026
- WK GROUP(02535.HK)2026 Interim Report - Profit Attributable to Shareholders stood at loss of HKD 11.52 million, turned into a loss from a profit YoY
- CLOUDBREAK-B(02592.HK)2026 Interim Report - Profit Attributable to Shareholders stood at loss of USD 47.95 million, turned into a loss from a profit YoY